Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

25.48 -0.13 (-0.51%)
Streaming Delayed Price Updated: 9:44 AM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,839
Open 25.45
Bid (Size) 25.47 (200)
Ask (Size) 25.55 (100)
Prev. Close 25.61
Today's Range 25.35 - 25.58
52wk Range 12.72 - 27.69
Shares Outstanding 114,998,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? ↗
Focused on monoclonal antibody therapies for autoimmune diseases, this biotech just reported a significant insider buy in public filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunovant Inc (NASDAQ:IMVT) Stock Falls 10% on Q2 FY2026 Earnings and Corporate Updates ↗
Immunovant stock drops 10% despite meeting Q2 FY2026 earnings estimates. The sell-off is driven by investor reaction to clinical pipeline updates for its anti-FcRn therapies. 
Via Chartmill

Performance

YTD
+1.2%
+1.2%
1 Month
+12.0%
+12.0%
3 Month
+58.7%
+58.7%
6 Month
+59.2%
+59.2%
1 Year
+6.7%
+6.7%

More News

Read More
News headline image
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Earnings Scheduled For November 10, 2025 ↗
Via Benzinga
News headline image
Insights into Immunovant's Upcoming Earnings ↗
Via Benzinga
News headline image
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗
Via Benzinga
News headline image
IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Why Immunovant Stock Blasted Higher Today ↗
Via The Motley Fool
News headline image
IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Immunovant Posts 34% R&D Jump in Q1 ↗
Via The Motley Fool
News headline image
IMVT INVESTIGATION ALERT: Pittsburgh Law Office of Alfred G. Yates Jr. PC Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
Via ACCESS Newswire
News headline image
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence ↗
Via Stocktwits
News headline image
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Via Benzinga
News headline image
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift ↗
Via Investor's Business Daily
Topics Government
News headline image
Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated ↗
Via Stocktwits
Topics Government Retirement Stocks
News headline image
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
From Roivant Sciences
Via GlobeNewswire
News headline image
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data ↗
Via Benzinga
News headline image
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled. ↗
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity ↗
Via Investor's Business Daily
News headline image
High Frequency Trading, PPI Misreads Helped Fuel a Short Squeeze... Now What ↗
Via Talk Markets
Topics Economy Stocks
News headline image
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases ↗
Via Investor's Business Daily

Frequently Asked Questions

Is Immunovant, Inc. - Common Stock publicly traded?
Yes, Immunovant, Inc. - Common Stock is publicly traded.
What exchange does Immunovant, Inc. - Common Stock trade on?
Immunovant, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immunovant, Inc. - Common Stock?
The ticker symbol for Immunovant, Inc. - Common Stock is IMVT on the Nasdaq Stock Market
What is the current price of Immunovant, Inc. - Common Stock?
The current price of Immunovant, Inc. - Common Stock is 25.48
When was Immunovant, Inc. - Common Stock last traded?
The last trade of Immunovant, Inc. - Common Stock was at 12/30/25 09:44 AM ET
What is the market capitalization of Immunovant, Inc. - Common Stock?
The market capitalization of Immunovant, Inc. - Common Stock is 2.93B
How many shares of Immunovant, Inc. - Common Stock are outstanding?
Immunovant, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.